Drugs / UVAX-1197
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06541093 | Jan 2024 → Mar 2025 | AIDS-related disorder, HIV infectious disease | Uvax Bio LLC | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06905275 | Jul 2025 → Jul 2027 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UVAX-1197 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06905275 ↗ |
| Modality | Vaccine | “Both UVAX-1197 and UVAX-1107 are protein nanoparticle vaccines displaying an uncleaved, prefusion-optimized (UFO) envelope (Env) glycoprotein from HIV-1 BG505 (BG505-UFO).” NCT06541093 ↗ |
| Route | Intramuscular | “Priming vaccinations of adjuvanted UVAX-1107 (full dose, administered in 0.5ml intramuscular injection) on Days 1 and 57 followed by boosting vaccinations of adjuvanted...” NCT06541093 ↗ |